At a glance
ClinicalIndex Comparison RecordPhase 3Recruiting· 324 target
Drug / intervention
Alteplasedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05856851Phase 3RecruitingUpdate OverdueUpdated 21mo ago · Completion was 6mo agoEnrollment Stalled
Update Overdue
Intra-arterial Alteplase for Acute Ischemic Stroke After Mechanical Thrombectomy (PEARL): A Multicenter, Prospective, Open-label, Blinded Endpoint, Randomized Controlled Trial
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University·interventional·Posted May 12, 2023·Updated Sep 3, 2024
In Brief
A Phase 3 clinical trial evaluating Alteplase for Stroke, Acute Ischemic. Currently recruiting, targeting 324 participants across 2 sites.
Signals
Enrollment appears stalled
Detailed Summary
A multicenter, prospective, open-label, blinded endpoint, randomized controlled trial aiming at evaluating the efficacy and safety of intra-arterial recombinant human tissue plasminogen activator (rt-PA) after successful recanalization of acute large vessel occlusion in the anterior circulation by mechanical thrombectomy in improving the 90-day functional outcome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStroke, Acute Ischemic
CountriesChina
CollaboratorsShenzhen Hospital of Southern Medical University
Timeline
Phase 3RecruitingOverdue
202420252026
First PostedMay 2023
Enrollment StartAug 2023
Primary CompletionDec 2025
TodayJul 2026
First PostedMay 12, 2023
Enrollment StartAug 1, 2023
Primary CompletionDec 1, 2025
TodayJul 1, 2026
Enrollment to primary: 2.3 yearsPosted 3.1 years ago
Interventions
Alteplasedrug
See arm/group descriptions.